Primary Care Physicians’ Perspective on SGLT2 Inhibitors for Chronic Kidney Disease

Primary Care Physicians’ Perspective on SGLT2 Inhibitors for Chronic Kidney Disease

Saved in:

Bibliographic Details
Main Authors:	Sky Wei Chee Koh, FCFP, Ming Yi Lai, MBBChir, Choon Kit Leong, FCFP, Joelle Lam, DIP, Han Shi Jocelyn Chew, PhD, Clara Lee Ying Ngoh, FAMS
Format:	Article
Language:	English
Published:	Elsevier 2025-06-01
Series:	Kidney Medicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S259005952500038X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

COVID-19 vaccination strategy in Singapore: perspectives and lessons from primary care
by: Sky Wei Chee Koh, et al.
Published: (2024-12-01)

Cost Analysis of DPP4 and SGLT2 Inhibitors - “Dilemma of the Prescribing Physician - Which Brand to Choose?”
by: Hiteswar Saikia, et al.
Published: (2024-06-01)

A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD
by: Jheng-Yan Wu, et al.
Published: (2025-08-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Role of SGLT2 inhibitors in the treatment of visceral obesity
by: M. A. Druzhilov, et al.
Published: (2021-02-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Osteomyelitis Pubis After Initiation of an SGLT2 Inhibitor
by: Adriana Nadeau, et al.
Published: (2022-10-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients
by: Huai Heng Loh, et al.
Published: (2025-03-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
by: Mohamed Alhemeiri, et al.
Published: (2022-01-01)

A Review on the Relationship between SGLT2 Inhibitors and Cancer
by: Hao-Wen Lin, et al.
Published: (2014-01-01)

Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs
by: Divya Rajagopal, et al.
Published: (2024-10-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Impact of SGLT2 Inhibitors on Left Ventricular Remodeling in Diabetic Patients with Acute Myocardial Infarction
by: Jun Wan MD, et al.
Published: (2024-12-01)

Complexity in primary care: Beyond multimorbidity in Healthier SG
by: Sky Wei Chee Koh, et al.
Published: (2025-02-01)

The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients
by: Jia-Yuh Sheu, et al.
Published: (2024-11-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism
by: Brett W. Sperry, MD, et al.
Published: (2025-08-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis
by: Nikita Ermolaev, et al.
Published: (2025-03-01)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024-11-01)

Is it Time to Expand the Use of SGLT2 Inhibitors in Kidney Transplant Recipients?
by: Kajaree Giri, et al.
Published: (2025-03-01)

Mottling as an early sign of euglycemic ketoacidosis induced by SGLT-2 inhibitors
by: Besard Memeti, et al.
Published: (2025-03-01)

Factors affecting disease progression in early-stage chronic kidney disease in a multi-ethnic, southeast Asian primary care population
by: Hui Qi Koh, et al.
Published: (2025-08-01)

SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
by: Marlena Stielow, et al.
Published: (2025-07-01)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
by: Emily Brown, et al.
Published: (2021-01-01)

SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America
by: José L. Daza, et al.
Published: (2025-04-01)

WCN24-1447 SGLT2 INHIBITORS AND KIDNEY SURVIVAL IN PREDIALYSIS CARE
by: Augusto Cesar Soares dos Santos Junior, et al.
Published: (2024-04-01)

Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety
by: Bing Zhang, et al.
Published: (2025-07-01)

Enhancing Heart Health: Expanding the Use of SGLT2 Inhibitors in Cardiovascular Disease
by: Manahil Mubeen, et al.
Published: (2025-06-01)

Severe hyperchloremic metabolic acidosis with SGLT2 inhibitors in patients with urinary diversion
by: Carolina Gomes, et al.
Published: (2025-05-01)

The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation.
by: Yongin Cho, et al.
Published: (2025-01-01)

Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome
by: Juan Guerrero-Mauvecin, et al.
Published: (2025-06-01)

The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
by: J. Karalliedde
Published: (2021-04-01)